CLDX analyst estimates
Celldex Therapeutics (CLDX) analyst ratings, the average price target and its range, and every firm's latest call.
CLDX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 23, 2026 | Morgan Stanley | Celldex price target raised to $57 from $50 at Morgan Stanley | $57.00 |
| Sep 23, 2026 | Leerink Partners | Celldex price target raised to $88 from $70 at Leerink | $88.00 |
| Sep 22, 2026 | Stifel Nicolaus | Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX) | $68.00 |
| Sep 22, 2026 | H.C. Wainwright | Celldex price target raised to $64 from $42 at H.C. Wainwright | $64.00 |
| Sep 10, 2026 | Morgan Stanley | Celldex price target raised to $50 from $46 at Morgan Stanley | $50.00 |
| Aug 7, 2026 | Barclays | Celldex price target raised to $53 from $48 at Barclays | $53.00 |
| Jul 29, 2026 | Wells Fargo | Celldex price target raised to $72 from $48 at Wells Fargo | $72.00 |
| Jul 22, 2026 | Leerink Partners | Celldex price target lowered to $70 from $78 at Leerink | $70.00 |
| Jul 22, 2026 | Canaccord Genuity | Celldex price target lowered to $60 from $62 at Canaccord | $60.00 |
| Jul 22, 2026 | Morgan Stanley | Celldex price target lowered to $40 from $44 at Morgan Stanley | $40.00 |
| Jul 22, 2026 | Wells Fargo | Celldex price target lowered to $48 from $54 at Wells Fargo | $48.00 |
| Jul 22, 2026 | Cantor Fitzgerald | Celldex price target lowered to $61 from $67 at Cantor Fitzgerald | $61.00 |
| Jul 20, 2026 | Guggenheim | Celldex price target raised to $100 from $90 at Guggenheim | $100.00 |
| Jun 10, 2026 | UBS | Celldex price target raised to $45 from $38 at UBS | $45.00 |
| May 13, 2026 | Wells Fargo | Celldex price target raised to $54 from $38 at Wells Fargo | $54.00 |
- 11 firms rate CLDX: 10 buy, 1 hold, 0 sell.
- The average price target is $66.80 from 10 analysts, from $45.00 to $100.00.
Updated 2026-11-03 12:28 UTC